MAY 04, 2020 11:52 AM PDT

A Retroactive Study Finds an Immunotherapy Effective as a Third-Line Therapy

WRITTEN BY: Jasper Cantrell

Cancer is a particularly persistent disease. Many therapies are composed of one or more different treatments. These treatments are referred to as first-line, second-line, and so on. First-line treatments are often the best available option, with second line treatments being the next best option should the first fail to induce full remission. Ramucirumab is an example of second-line treatment in gastric and other cancers. Recently it has been increasingly used as a third-line treatment or later. There is a lack of research in its effectiveness as a third-line treatment, and a group from Japan decided to retroactively investigate.

Gastric cancer is the third leading cause of cancer-related deaths in the world. Ramucirumab was initially approved for the treatment of advanced gastric cancer, and this is where the group started. They gathered a sample of fifty-one patients with a variety of advanced gastric cancers, forty-four of which having been treated at least twice before. They began treating all patients with ramucirumab and followed the results.

Of the fifty-one patients, forty-seven patients had to halt their ramucirumab treatments due to cancer progression or other adverse events. Out of the sample, there was a 17% disease control rate and a 2% response rate. There were a few patients who showed no effect on treatment. Thirty-eight of the patients had adverse effects during the trial, however, no patients had fatal reactions.

The primary variables the group used to determine the success or failure of this study were progression-free survival (PFS) and overall survival (OS) of the patients in the trial. Previous works had ramucirumab achieve a PFS of 2.1 and 1.6, with an OS of 5.2 and 7.3. This group's findings were similar, with a PFS of 1.8 and an OS of 5.1. The group goes on to postulate that these numbers are identical to figures from second-line treatments. Any differences in the numbers are likely due to the selectivity of the patients' treatments.

Ramucirumab maintains its effectiveness as a third-line treatment with little to no difference in PFS or OS. The available options for treatment over the years have increased, with many new chemotherapies and immunotherapies available. This has led ramucirumab to be pushed to a third-line treatment. The group concludes that ramucirumab is still valid as a third-line treatment for advanced gastric cancers, concluding "Ramucirumab monotherapy demonstrates acceptable efficacy and feasibility as third- or later-line treatment for AGC. We consider physicians might choose this therapy as a salvage-line treatment option for AGC refractory to the standard therapies."

Sources: Journal of Clinical Oncology, OncLive TV
 

About the Author
  • Hey everyone! My name is Jasper and, considering I am pretty new here to Labroots, I figured I would introduce myself. I received my bachelor’s from the University of California at Riverside back in 2016. I started off my career a few years ago with a job at a University over in New York, before moving over into the industry. I'm happy to be writing content for Labroots, and I hope you enjoy it!
You May Also Like
APR 09, 2021
Cancer
Employing machine-learning to identify the biological languages of cancer and Alzheimer's
APR 09, 2021
Employing machine-learning to identify the biological languages of cancer and Alzheimer's
In a study published in the scientific journal PNAS, researchers from St. John's College and the  University of ...
JUN 07, 2021
Health & Medicine
Higher Incidence of Breast Cancer in Polluted Urban Areas
JUN 07, 2021
Higher Incidence of Breast Cancer in Polluted Urban Areas
A Taiwanese study looked at the incidence of breast cancer in areas of Taiwan with varying levels of air pollutants. Air ...
JUN 07, 2021
Cell & Molecular Biology
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
JUN 07, 2021
Overcoming Challenges to Detect Apoptosis in 3D Cell Structures
Researchers are increasingly relying on cells grown in three-dimensional (3D) structures to help answer their research q ...
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
JUL 12, 2021
Cell & Molecular Biology
A Molecule From the Gut Microbiome May Fight Tumors
JUL 12, 2021
A Molecule From the Gut Microbiome May Fight Tumors
The more we learn abut the gut microbiome, the more it seems that the microorganisms in our gastrointestinal tracts can ...
JUL 16, 2021
Cancer
Exercise Slows Growth of Bowel Cancer Cells
JUL 16, 2021
Exercise Slows Growth of Bowel Cancer Cells
Exercise releases molecules into the bloodstream that reduce the growth of bowel cancer cells, say researchers from the ...
Loading Comments...